Cellectar Reports Financial Results for the Third Quarter 2023 and Provides a Corporate Update
FLORHAM PARK, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced financial results for the third quarter…